Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone/levofloxacin - NTC Pharma

Next Previous
Search
Drug Profile

Dexamethasone/levofloxacin - NTC Pharma

Alternative Names: Levofloxacin/dexamethasone

Latest Information Update: 24 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NTC
  • Class Anti-inflammatories; Antibacterials; Antiemetics; Antineoplastics; Eye disorder therapies; Fluorinated steroids; Fluoroquinolones; Glucocorticoids; Non-opioid analgesics; Pregnadienetriols; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Immunosuppressants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ocular inflammation; Ophthalmic infections

Most Recent Events

  • 24 Apr 2022 No development reported - Phase-III for Ocular inflammation in Germany, Russia, Spain, Italy (Ophthalmic) (NTC Pharma website, April 2022)
  • 24 Apr 2022 No development reported - Phase-III for Ophthalmic infections (Prevention) in Germany, Spain, Russia, Italy (Ophthalmic) (NTC Pharma website, April 2022)
  • 17 Jun 2020 NTC Pharma grants license and distribution rights to Taro Pharmaceutical Industries for dexamethasone/levofloxacin in Israel

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top